Sana Biotechnology to Present at March 2026 Investor Conferences
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sana Biotechnology (NASDAQ: SANA) will present live at two investor conferences in March 2026, with webcasts and 30-day replays available.
Sana will present a business overview and update at the Cowen 46th Annual Health Care Conference on March 2, 2026 at 1:10 p.m. ET and at the Citizens Life Sciences Conference on March 11, 2026 at 1:40 p.m. ET. Webcasts are on the company Investor Relations page and replays remain for 30 days.
Details
News Market Reaction – SANA
On Feb 24, the first trading day after this news, SANA closed 3.93% above the previous close.
Data tracked by StockTitan Argus for the Feb 24 session.
Key Figures
- Cowen conference time
- 1:10 p.m. ET
- Cowen 46th Annual Health Care Conference on March 2, 2026
- Cowen conference date
- March 2, 2026
- SANA business overview presentation
- Citizens conference time
- 1:40 p.m. ET
- Citizens Life Sciences Conference on March 11, 2026
- Citizens conference date
- March 11, 2026
- SANA business overview presentation
- Conference count
- 2 conferences
- March 2026 investor events with webcasts
- Replay window
- 30 days
- Webcast replay availability after each conference
- Conference year
- 46th
- Cowen 46th Annual Health Care Conference
Historical Context
-
New EVP/CFO with long biopharma finance experience joining leadership team.
-
J.P. Morgan Healthcare Conference presentation with corporate overview webcast.
-
Nature Biotechnology publication of in vivo HSC gene editing using fusogen VLP platform.
-
December 2025 Citi and Evercore conference presentations with business updates.
-
Q3 2025 results, pipeline focus on SC451 and SG293, and extended cash runway.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in March. The presentations will feature a business overview and update.
- Sana will present at the Cowen 46th Annual Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026.
- Sana will present at the Citizens Life Sciences Conference at 1:40 p.m. ET on Wednesday, March 11, 2026.
The webcasts will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of each presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the Cowen 46th Annual Health Care Conference and the Citizens Life Sciences Conference; and the subject matter of the Company’s presentations at these conferences. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated November 6, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.